donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BLUE bluebird bio
6.340
+0.750+13.42%
Post Mkt Price
6.330
-0.01-0.16%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
-79.67% 1.52M -84.8% 1.95M -98.54% 3.66M -85% 1.61M
Operating revenue
-82.19% 1.33M -88.99% 1.41M -98.86% 2.85M -87.32% 1.36M
Cost of revenue
-93.12% 1.75M 264.31% 8.31M 620.11% 38.86M 145.63% 3.68M
Gross profit
98.74% -226K -160.54% -6.37M -114.35% -35.2M -122.54% -2.08M
Operating expense
-54.89% 100.54M -52.77% 113.98M -39.43% 529.92M -38.06% 132.59M
Selling and administrative expenses
-53.3% 36.69M -58.44% 36.11M -26.81% 209.97M -30.88% 53.21M
Research and development costs
-55.76% 63.84M -49.59% 77.88M -45.58% 319.95M -42.1% 79.38M
Operating profit
58.15% -100.76M 47.87% -120.35M 10.23% -565.11M 34.26% -134.67M
Net non-operating interest income expense
-60.36% 174K -85.07% 106K -92.38% 879K -88.6% 146K
Non-operating interest income
-60.36% 174K -85.07% 106K -92.38% 879K -88.6% 146K
Other net income (expense)
139.59% 449K -107.84% -1.91M 5544.12% 1.85M -42.33% 2.28M
Special income (charges)
-14025.53% -6.64M -- -- -498.9% -25.8M -214.14% -1M
-Less:Restructuring and merger&acquisition
14025.53% 6.64M -- -- 498.9% 25.8M 214.14% 1M
Other non- operating income (expenses)
752.07% 7.09M -107.72% -1.91M 525.28% 27.65M 6.59% 3.28M
Income before tax
58.53% -100.14M 40.63% -122.15M 9% -562.38M 33.76% -132.24M
Income tax
0 0 -62.39% 258K -64.82% 89K
Net income
58.57% -100.14M 40.65% -122.15M -32.44% -819.38M 22.43% -155.05M
Net income continuous Operations
58.57% -100.14M 40.65% -122.15M 9.06% -562.64M 33.79% -132.33M
Net income discontinuous operations
-- 0 -- 0 -- -256.74M -- -22.73M
Minority interest income
Net income attributable to the parent company
58.57% -100.14M 40.65% -122.15M -32.44% -819.38M 22.43% -155.05M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
58.57% -100.14M 40.65% -122.15M -32.44% -819.38M 22.43% -155.05M
Basic earnings per share
62.01% -1.36 45.93% -1.66 -19.5% -11.89 28.9% -2.14
Diluted earnings per share
62.01% -1.36 45.93% -1.66 -19.5% -11.89 28.9% -2.14
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...